• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Ind-Swift Laboratories Limited — Updates, 14-01-2026: General Updates

    14-01-2026 | 06:47 pm

    Ind-Swift Labs reset its strategy: divested API/CRAMS for ₹1,650 Cr, becoming net debt-free. Now a pure-play formulations platform with ₹550 Cr revenue, targeting ₹1,200+ Cr by FY29. Viatris partnership & own-brand expansion drive future growth, with ₹200-220 Cr incremental revenue from Viatris by FY27.

    No comments yet. Be the first to comment!

    All announcements from Ind-Swift Laboratories Limited